prolaio, Inc.

Prolaio, Inc. is a healthcare technology company that enhances cardiovascular care through a sophisticated platform that connects patients, healthcare providers, and researchers, ensuring efficient data collection and actionable insights. Prolaio, Inc. specializes in a technology-enabled platform focused on heart care.

Founded in 2022 in Chicago, US, the company has executed one deal to date. The founder's history is not detailed, and there are no known subsidiaries. In March 2025, Kardigan, a portfolio company of ARCH Venture Partners, Perceptive Advisors, and Sequoia Capital, acquired prolaio, Inc. for an undisclosed amount.

Prolaio specializes in a technology-enabled platform designed to enhance heart care by uniting patients, care teams, and researchers. The company’s core product offerings include FDA-cleared software that collects real-world clinical data and utilizes advanced algorithms to provide actionable insights for healthcare providers. These products enable continuous patient monitoring and facilitate proactive care, ultimately aiming to improve patient outcomes in cardiology. Prolaio's solutions cater to a diverse clientele, including healthcare providers, research institutions, and patients, primarily operating in the United States and expanding into over 26 countries worldwide.

The platform's functionalities simplify research workflows, optimize treatment decisions, and support clinical trials, making it a vital tool in addressing the challenges posed by heart disease. Prolaio generates revenue through a subscription-based model for its software services, targeting healthcare providers, hospitals, and research institutions. Clients engage with the company by subscribing to its platform, allowing access to high-density clinical insights and data analytics that aid in patient management and clinical research. The transactions typically involve annual or monthly subscriptions, with pricing structures designed to accommodate various organizational sizes and needs.

Prolaio’s flagship service offerings include advanced patient monitoring and predictive analytics tools, which are integral to their value proposition in precision cardiology. Revenue is directly linked to the performance of these services, as clients leverage the platform’s capabilities to enhance patient care and streamline research efforts. With the recent acquisition by Kardigan in March 2025, prolaio, Inc. 's technology platform for cardiovascular data collection and analytics will be leveraged for broader applications.

The acquisition aims to enhance Kardigan’s capabilities by integrating Prolaio's innovative solutions. Future growth strategies involve expanding access to the CV data collection platform across new markets and regions, specifically targeting healthcare systems in Europe and Asia by 2026. The acquisition's rationale is to provide Kardigan with advanced tools for data analysis and patient monitoring, ultimately contributing to enhanced cardiovascular research and care.